Prestige Consumer Healthcare (PBH) Competitors

$44.92 -1.55 (-3.34%)

Closing price 03:59 PM Eastern

Extended Trading

$44.98 +0.06 (+0.14%)

As of 05:11 PM Eastern

PBH vs. CRNX, BLTE, LNTH, LQDA, and AMRX

Should you buy Prestige Consumer Healthcare stock or one of its competitors? Prestige Consumer Healthcare's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Belite Bio (BLTE), Lantheus (LNTH), Liquidia (LQDA), and Amneal Pharmaceuticals (AMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Prestige Consumer Healthcare compare to Crinetics Pharmaceuticals?

Prestige Consumer Healthcare (NYSE:PBH) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Prestige Consumer Healthcare presently has a consensus target price of $70.75, suggesting a potential upside of 57.51%. Crinetics Pharmaceuticals has a consensus target price of $81.00, suggesting a potential downside of 4.65%. Given Prestige Consumer Healthcare's higher possible upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

100.0% of Prestige Consumer Healthcare shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 1.5% of Prestige Consumer Healthcare shares are owned by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Prestige Consumer Healthcare has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market.

Prestige Consumer Healthcare has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prestige Consumer Healthcare	$1.09B	1.95	$190.30M	$3.57	12.58
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

Prestige Consumer Healthcare has a net margin of 15.57% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Prestige Consumer Healthcare's return on equity of 11.39% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prestige Consumer Healthcare	15.57%	11.39%	5.66%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

In the previous week, Crinetics Pharmaceuticals' average media sentiment score of 1.89 beat Prestige Consumer Healthcare's score of 0.50 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Prestige Consumer Healthcare	Positive
Crinetics Pharmaceuticals	Very Positive

Summary

Prestige Consumer Healthcare beats Crinetics Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Prestige Consumer Healthcare has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Prestige Consumer Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Prestige Consumer Healthcare	$1.09B	1.95	$190.30M	$3.57	12.58

Prestige Consumer Healthcare has a net margin of 15.57% compared to Belite Bio's net margin of 0.00%. Prestige Consumer Healthcare's return on equity of 11.39% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Belite Bio has a beta of -1.23, suggesting that its share price is 223% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

Belite Bio currently has a consensus price target of $218.73, suggesting a potential upside of 27.94%. Prestige Consumer Healthcare has a consensus price target of $70.75, suggesting a potential upside of 57.51%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Belite Bio had 2 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 2 mentions for Belite Bio and 0 mentions for Prestige Consumer Healthcare. Belite Bio's average media sentiment score of 1.13 beat Prestige Consumer Healthcare's score of 0.50 indicating that Belite Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Belite Bio	Positive
Prestige Consumer Healthcare	Positive

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Prestige Consumer Healthcare beats Belite Bio on 10 of the 15 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

Lantheus presently has a consensus target price of $108.11, suggesting a potential upside of 7.52%. Prestige Consumer Healthcare has a consensus target price of $70.75, suggesting a potential upside of 57.51%. Given Prestige Consumer Healthcare's higher probable upside, analysts plainly believe Prestige Consumer Healthcare is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Lantheus has a net margin of 17.69% compared to Prestige Consumer Healthcare's net margin of 15.57%. Lantheus' return on equity of 28.10% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Lantheus has higher revenue and earnings than Prestige Consumer Healthcare. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.26	$233.56M	$4.14	24.29
Prestige Consumer Healthcare	$1.09B	1.95	$190.30M	$3.57	12.58

In the previous week, Lantheus had 2 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 2 mentions for Lantheus and 0 mentions for Prestige Consumer Healthcare. Lantheus' average media sentiment score of 0.87 beat Prestige Consumer Healthcare's score of 0.50 indicating that Lantheus is being referred to more favorably in the media.

Company	Overall Sentiment
Lantheus	Positive
Prestige Consumer Healthcare	Positive

99.1% of Lantheus shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 1.7% of Lantheus shares are held by company insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Lantheus beats Prestige Consumer Healthcare on 13 of the 16 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

Prestige Consumer Healthcare has higher revenue and earnings than Liquidia. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	37.81	-$68.92M	$1.37	48.82
Prestige Consumer Healthcare	$1.09B	1.95	$190.30M	$3.57	12.58

Liquidia has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

64.5% of Liquidia shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Liquidia has a net margin of 30.74% compared to Prestige Consumer Healthcare's net margin of 15.57%. Liquidia's return on equity of 149.65% beat Prestige Consumer Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

In the previous week, Liquidia had 12 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 12 mentions for Liquidia and 0 mentions for Prestige Consumer Healthcare. Liquidia's average media sentiment score of 0.82 beat Prestige Consumer Healthcare's score of 0.50 indicating that Liquidia is being referred to more favorably in the media.

Company	Overall Sentiment
Liquidia	Positive
Prestige Consumer Healthcare	Positive

Liquidia currently has a consensus price target of $98.08, suggesting a potential upside of 46.66%. Prestige Consumer Healthcare has a consensus price target of $70.75, suggesting a potential upside of 57.51%. Given Prestige Consumer Healthcare's higher possible upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Summary

Liquidia beats Prestige Consumer Healthcare on 12 of the 17 factors compared between the two stocks.

How does Prestige Consumer Healthcare compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Prestige Consumer Healthcare (NYSE:PBH) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

Amneal Pharmaceuticals has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Prestige Consumer Healthcare has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 100.0% of Prestige Consumer Healthcare shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 1.5% of Prestige Consumer Healthcare shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals presently has a consensus target price of $20.14, suggesting a potential upside of 7.66%. Prestige Consumer Healthcare has a consensus target price of $70.75, suggesting a potential upside of 57.51%. Given Prestige Consumer Healthcare's higher probable upside, analysts clearly believe Prestige Consumer Healthcare is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Prestige Consumer Healthcare	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.17

Prestige Consumer Healthcare has a net margin of 15.57% compared to Amneal Pharmaceuticals' net margin of 5.05%. Prestige Consumer Healthcare's return on equity of 11.39% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Prestige Consumer Healthcare	15.57%	11.39%	5.66%

Prestige Consumer Healthcare has lower revenue, but higher earnings than Amneal Pharmaceuticals. Prestige Consumer Healthcare is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.98	$72.06M	$0.49	38.18
Prestige Consumer Healthcare	$1.09B	1.95	$190.30M	$3.57	12.58

In the previous week, Amneal Pharmaceuticals had 6 more articles in the media than Prestige Consumer Healthcare. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 0 mentions for Prestige Consumer Healthcare. Prestige Consumer Healthcare's average media sentiment score of 0.50 beat Amneal Pharmaceuticals' score of 0.43 indicating that Prestige Consumer Healthcare is being referred to more favorably in the news media.

Company	Overall Sentiment
Amneal Pharmaceuticals	Neutral
Prestige Consumer Healthcare	Positive

Summary

Amneal Pharmaceuticals beats Prestige Consumer Healthcare on 9 of the 16 factors compared between the two stocks.

Get Prestige Consumer Healthcare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBH vs. The Competition

Export

Metric	Prestige Consumer Healthcare	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.13B	$12.42B	$7.19B	$22.96B
Dividend Yield	N/A	2.64%	2.57%	3.59%
P/E Ratio	12.58	797.25	274.66	28.22
Price / Sales	1.95	801.14	683.58	86.56
Price / Cash	9.00	87.33	77.01	33.29
Price / Book	1.13	10.49	10.46	4.67
Net Income	$190.30M	$2.81B	$3.48B	$1.07B
7 Day Performance	-4.42%	2.81%	0.88%	-1.65%
1 Month Performance	-11.34%	3.29%	0.03%	-3.58%
1 Year Performance	-29.97%	3.57%	18.28%	7.58%

Prestige Consumer Healthcare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBH Prestige Consumer Healthcare	2.9041 of 5 stars	$44.92 -3.3%	$70.75 +57.5%	-27.2%	$2.13B	$1.09B	12.58	890	High Trading Volume
CRNX Crinetics Pharmaceuticals	1.563 of 5 stars	$84.95 flat	$81.00 -4.6%	N/A	$9.01B	$7.70M	N/A	210	Positive News
BLTE Belite Bio	3.7059 of 5 stars	$195.38 +0.9%	$214.64 +9.9%	+133.4%	$7.89B	N/A	N/A	10
LNTH Lantheus	3.6072 of 5 stars	$100.71 -0.3%	$108.11 +7.3%	+98.3%	$6.57B	$1.56B	24.33	1,193	Positive News
LQDA Liquidia	3.7691 of 5 stars	$67.44 -1.8%	$98.08 +45.4%	+173.6%	$6.03B	$158.32M	49.18	50	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:PBH) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prestige Consumer Healthcare (PBH) Competitors

PBH vs. CRNX, BLTE, LNTH, LQDA, and AMRX

How does Prestige Consumer Healthcare compare to Crinetics Pharmaceuticals?

Summary

How does Prestige Consumer Healthcare compare to Belite Bio?

Summary

How does Prestige Consumer Healthcare compare to Lantheus?

Summary

How does Prestige Consumer Healthcare compare to Liquidia?

Summary

How does Prestige Consumer Healthcare compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH vs. The Competition

Prestige Consumer Healthcare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prestige Consumer Healthcare (PBH) Competitors

PBH vs. CRNX, BLTE, LNTH, LQDA, and AMRX

How does Prestige Consumer Healthcare compare to Crinetics Pharmaceuticals?

Do analysts rate PBH or CRNX?

Do insiders and institutionals have more ownership in PBH or CRNX?

Which has more risk and volatility, PBH or CRNX?

Which has better earnings & valuation, PBH or CRNX?

Is PBH or CRNX more profitable?

Does the media prefer PBH or CRNX?

Summary

How does Prestige Consumer Healthcare compare to Belite Bio?

Which has preferable earnings & valuation, BLTE or PBH?

Is BLTE or PBH more profitable?

Which has more volatility & risk, BLTE or PBH?

Do analysts prefer BLTE or PBH?

Does the media favor BLTE or PBH?

Do institutionals & insiders have more ownership in BLTE or PBH?

Summary

How does Prestige Consumer Healthcare compare to Lantheus?

Do analysts recommend LNTH or PBH?

Which has more volatility & risk, LNTH or PBH?

Is LNTH or PBH more profitable?

Which has preferable earnings and valuation, LNTH or PBH?

Does the media prefer LNTH or PBH?

Do institutionals and insiders have more ownership in LNTH or PBH?

Summary

How does Prestige Consumer Healthcare compare to Liquidia?

Which has better earnings & valuation, LQDA or PBH?

Which has more risk and volatility, LQDA or PBH?

Do insiders and institutionals have more ownership in LQDA or PBH?

Is LQDA or PBH more profitable?

Does the media prefer LQDA or PBH?

Do analysts recommend LQDA or PBH?

Summary

How does Prestige Consumer Healthcare compare to Amneal Pharmaceuticals?

Which has more volatility and risk, AMRX or PBH?

Do insiders & institutionals have more ownership in AMRX or PBH?

Do analysts recommend AMRX or PBH?

Is AMRX or PBH more profitable?

Which has higher valuation & earnings, AMRX or PBH?

Does the media favor AMRX or PBH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH vs. The Competition

Prestige Consumer Healthcare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools